TY - JOUR
T1 - Effect of unlabelled monoclonal antibody (MoAb) on biodistribution of111indium labelled (MoAb)
AU - Lamki, Lamk M.
AU - Murray, James L.
AU - Rosenblum, Michael G.
AU - Patt, Yehuda Z.
AU - Babaian, Richard
AU - Unger, Michael W.
PY - 1988/8
Y1 - 1988/8
N2 - We have evaluated immunoscintigraphy in cancer patients using four111In-labelled murine monoclonal antibodies (MoAb): 96.5 (anti-P97 of melanoma), ZME-018 (anti-high molecular weight antibody of melanoma), ZCE-025 (anti-CEA for colon cancer) and PAY-276 (anti-prostatic acid phosphatase for prostatic cancer). The effect of increasing the doses of unlabelled MoAb (co-infused with 1 mg labelled MoAb) on the relative body distribution of each labelled MoAb was assessed. Localization in the liver decreased significantly in all cases, with increasing MoAb dose, except for ZME-018. Localization in other organs increased significantly as the liver activity decreased. The spleen activity, however, fell in the case of MoAb ZME-018. Blood-pool activity increased with MoAb dose in all four MoAbs. These findings correlated with the rise in the detection rate of metastases, the plasma half-life, and other pharmacokinetic parameters. However, the dose level at which this correlation occurred varied with each antibody. These data demonstrate that co-infusion of unlabelled MoAb with111In-labelled MoAb could alter the organ distribution, pharmacokinetics and tumour uptake in a favourable manner, though the degree to which this occurs depends on the antibody in question.
AB - We have evaluated immunoscintigraphy in cancer patients using four111In-labelled murine monoclonal antibodies (MoAb): 96.5 (anti-P97 of melanoma), ZME-018 (anti-high molecular weight antibody of melanoma), ZCE-025 (anti-CEA for colon cancer) and PAY-276 (anti-prostatic acid phosphatase for prostatic cancer). The effect of increasing the doses of unlabelled MoAb (co-infused with 1 mg labelled MoAb) on the relative body distribution of each labelled MoAb was assessed. Localization in the liver decreased significantly in all cases, with increasing MoAb dose, except for ZME-018. Localization in other organs increased significantly as the liver activity decreased. The spleen activity, however, fell in the case of MoAb ZME-018. Blood-pool activity increased with MoAb dose in all four MoAbs. These findings correlated with the rise in the detection rate of metastases, the plasma half-life, and other pharmacokinetic parameters. However, the dose level at which this correlation occurred varied with each antibody. These data demonstrate that co-infusion of unlabelled MoAb with111In-labelled MoAb could alter the organ distribution, pharmacokinetics and tumour uptake in a favourable manner, though the degree to which this occurs depends on the antibody in question.
UR - http://www.scopus.com/inward/record.url?scp=0023719734&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023719734&partnerID=8YFLogxK
U2 - 10.1097/00006231-198808000-00004
DO - 10.1097/00006231-198808000-00004
M3 - Article
C2 - 3173914
AN - SCOPUS:0023719734
SN - 0143-3636
VL - 9
SP - 553
EP - 564
JO - Nuclear Medicine Communications
JF - Nuclear Medicine Communications
IS - 8
ER -